MaxorPlus Formulary Update: Stelara® Biosimilar

Last updated: May 7, 2025

Our formulary list is changing this year. We are moving to a biosimilar for Stelara®, a frequently prescribed medication for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. This is part of the overall biosimilars strategy at MaxorPlus, which is an effort to look out for value, member choice, and cost savings for our clients and members. 

MaxorPlus now has added Selarsdi® and Yesintek®, two biosimilar medications for Stelara, at parity with Stelara to our formularies. Account teams will share details as new products are added.

There are benefits to using biosimilars:

• With no clinically meaningful difference from reference products, interchangeable biosimilars are a safe and effective treatment option that may reduce plan and member costs.
• Moving to biosimilars allows members to have choices over which biosimilar products may best meet their healthcare needs, a decision made in coordination with their prescribing physician.

We will be updating our prior authorization criteria to reflect the formulary changes for 2025 and 2026. This is a dynamic situation where market conditions may change rapidly. MaxorPlus will provide updates and guidance accordingly.

To learn more about MaxorPlus, please visit https://www.maxor.com/maxorplus/.